BioTricity Inc. Files 8-K: Material Agreement & Equity Sales
Ticker: BTCY · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1630113
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
BioTricity filed an 8-K on 3/25 for a new material agreement and equity sales.
AI Summary
On March 25, 2024, BioTricity Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. This filing pertains to their operations as a medical device company specializing in remote patient monitoring.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate financial pressure or dilution for existing shareholders.
Key Players & Entities
- BIOTRICITY INC. (company) — Registrant
- March 25, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-40761 (identifier) — SEC File Number
- 203 Redwood Shores Parkway, Suite 600 Redwood City, California 94065 (address) — Principal Executive Offices
- (650) 832-1626 (phone_number) — Registrant's phone number
FAQ
What is the nature of the material definitive agreement entered into by BioTricity Inc. on March 25, 2024?
The specific details of the material definitive agreement are not disclosed in this 8-K filing, which only reports its entry.
What type of securities were involved in the unregistered sales reported by BioTricity Inc.?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the type of equity securities involved.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 25, 2024.
What is BioTricity Inc.'s principal executive office address?
BioTricity Inc.'s principal executive office is located at 203 Redwood Shores Parkway, Suite 600, Redwood City, California 94065.
What is BioTricity Inc.'s SEC File Number?
BioTricity Inc.'s SEC File Number is 001-40761.
Filing Stats: 2,236 words · 9 min read · ~7 pages · Grade level 15.2 · Accepted 2024-03-26 17:18:52
Key Financial Figures
- $0.001 B — ch registered Common Stock, Par Value $0.001 BTCY Nasdaq Capital Market Indicate
- $0.001 — s Series B Convertible Preferred Stock, $0.001 par value (the "Series B Preferred Stoc
- $9,090.91 — eferred Stock"), at a purchase price of $9,090.91 per share of Series B Convertible Prefe
- $1,000,000 — Preferred Stock, for gross proceeds of $1,000,000. At any time prior to the 30 th calenda
- $10,000 — B Preferred Stock has a stated value of $10,000 per share (the "Stated Value"). The S
- $3 — price. The initial conversion price is $3.50, subject to adjustment in the event
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex10-1.htm (EX-10.1) — 365KB
- ex10-2.htm (EX-10.2) — 121KB
- ex10-3.htm (EX-10.3) — 44KB
- 0001493152-24-011344.txt ( ) — 873KB
- btcy-20240325.xsd (EX-101.SCH) — 3KB
- btcy-20240325_lab.xml (EX-101.LAB) — 33KB
- btcy-20240325_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: March 26, 2024 BIOTRICITY INC. By: /s/ Waqaas Al-Siddiq Waqaas Al-Siddiq Chief Executive Officer